Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL005 (recombinant human thymosin β4) in acute myocardial infarction
ChiCTR2600127598Phase 2Not yet recruiting
- Sponsor
- Fuwai Hospital
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of thymosin beta-4 in myocardial infarction (MI) (3 arms), sponsored by Fuwai Hospital. Primary endpoints: Myocardial Infarct Size (g) at Day 90 and Percentage of Myocardial Infarct Size at Day 90. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
thymosin beta-4
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2600127598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127598.